Azalea Therapeutics is a biotechnology company based in Berkeley, California that develops precision genomic medicines by delivering genome‑editing tools directly to patient cells in vivo. Using its proprietary Envelope Delivery Vehicles (EDVs), the firm programs a patient’s own T cells inside the body to create cancer immunotherapies, aiming to simplify and scale cell‑based treatments.
No recent news for this company.